Podrobný výpis o publikaci

BAREŠ, Martin, Irena REKTOROVÁ, Robert JECH, Kateřina FARNÍKOVÁ, Jan ROTH, Evžen RŮŽIČKA, Petr KAŇOVSKÝ, Ivan REKTOR, Tomáš PAVLÍK, Leona UHLÍŘOVÁ a Jaroslav VYDLÁK. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?. Online. Journal of Neural Transmission. 2012, roč. 119, č. 3, s. 373–380. ISSN 0300-9564. Dostupné z: https://dx.doi.org/10.1007/s00702-011-0683-9. [citováno 2024-04-24]

Další formáty: BibTeX LaTeX RIS

TY  - JOUR
ID  - 976674
AU  - Bareš, Martin - Rektorová, Irena - Jech, Robert - Farníková, Kateřina - Roth, Jan - Růžička, Evžen - Kaňovský, Petr - Rektor, Ivan - Pavlík, Tomáš - Uhlířová, Leona - Vydlák, Jaroslav
PY  - 2012
TI  - Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?
JF  - Journal of Neural Transmission
VL  - 119
IS  - 3
SP  - 373–380
EP  - 373–380
SN  - 03009564
KW  - Wearing-off
KW  - Parkinson’s disease
KW  - Levodopa
KW  - WOQ-9
KW  - Epidemiology
N2  - EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson’s disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists’ assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0–2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists’ assessment of wearing-off symptoms and PD patients’ subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.
ER  -

Základní údaje
Originální název	Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?
Autoři	BAREŠ, Martin (203 Česká republika, garant, domácí), Irena REKTOROVÁ (203 Česká republika, domácí), Robert JECH (203 Česká republika), Kateřina FARNÍKOVÁ (203 Česká republika), Jan ROTH (203 Česká republika), Evžen RŮŽIČKA (203 Česká republika), Petr KAŇOVSKÝ (203 Česká republika), Ivan REKTOR (203 Česká republika, domácí), Tomáš PAVLÍK (203 Česká republika, domácí), Leona UHLÍŘOVÁ (203 Česká republika) a Jaroslav VYDLÁK (203 Česká republika)
Vydání	Journal of Neural Transmission, 2012, 0300-9564.

Další údaje
Originální jazyk	angličtina
Typ výsledku	Článek v odborném periodiku
Obor	30000 3. Medical and Health Sciences
Stát vydavatele	Rakousko
Utajení	není předmětem státního či obchodního tajemství
Impakt faktor	Impact factor: 3.052
Kód RIV	RIV/00216224:14110/12:00059524
Organizační jednotka	Lékařská fakulta
Doi	http://dx.doi.org/10.1007/s00702-011-0683-9
UT WoS	000300587900010
Klíčová slova anglicky	Wearing-off; Parkinson’s disease; Levodopa; WOQ-9; Epidemiology
Příznaky	Mezinárodní význam
Změnil	Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 16. 4. 2013 16:34.

Anotace
EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson’s disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists’ assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0–2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists’ assessment of wearing-off symptoms and PD patients’ subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.

Anotace

EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson’s disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists’ assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0–2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists’ assessment of wearing-off symptoms and PD patients’ subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.